NCT03912064 2026-01-05A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTDana-Farber Cancer InstitutePhase 1 Active not recruiting25 enrolled 17 charts
NCT02397720 2025-06-08Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer CenterPhase 2 Completed150 enrolled 17 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled